Edema agudo pulmonar, como causa secundaria de morbimortalidad cardiovascular: tratamiento actualizado

Abstract

Introduction: Acute cardiogenic lung edema is a clinical syndrome in which the heart is unable to pump the amount of blood to meet the needs of the body. Worldwide, it is an important cause of morbidity and mortality, affecting mainly the elderly population. 65 years old. In our country in 2016 according to the I.N.E.C reported 963 deaths due to heart failure. Objective: To establish updated treatment of pulmonary edema to reduce cardiovascular morbidity and mortality. Methods: The articles used were obtained from data platforms such as PubMed, Google Scholar, Medscape and ScienceDirect; in the period of time from 2014 to 2018; including: clinical practice protocols, clinical practice guidelines, consensus documents, systemic reviews and analytical studies. Results: 37 articles were selected that met the objectives set and with the quality standards; on which the current treatment for acute pulmonary edema was investigated. Conclusions: It is concluded that the current treatment for acute pulmonary edema is based on alleviating the symptoms and signs. In addition to the traditional treatment they include; furosemide, nitroglycerin, dobutamine, nitroglycerin. Currently in the investigations of this research study indicate neseritide, milrinone, levosimendan, which have been well accepted but there are no conclusive studies to demonstrate their effectiveness. However, Carperitide as an option according to studies has been shown to reduce symptoms and signs of acute pulmonary edema.